Stockwinners Market Radar for February 12, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Meta (META) has delayed finalizing multiple teams' budgets while it prepares a fresh round of job cuts as Mark Zuckerberg's plan to contain costs in his "year of efficiency" causes disruption at the social media company, Financial Times' Hannah Murphy and Cristina Criddle report. Two Meta employees familiar with the situation told the Financial Times that there had been a lack of clarity about budgets or future headcount in recent weeks. As a result, staff have complained that "zero work" is getting done as managers have been unable to plan their coming workloads, the employees said. 2. FIS (FIS) is making preparations to break up and plans to pursue a tax-free spin-off of its merchant business, David French, Anirban Sen and Milana Vinn of Reuters report, citing people familiar with the matter. The spinoff will take many months to be completed, and FIS will also entertain any acquisition offers for the unit during this period, sources told Reuters. The company could announce the spinoff as early as next week, the people added. 3. A revitalized Hertz (HTZ) is set to put investors in "the driver's seat," to borrow a phrase from its 1960s ad campaign, Andrew Bary writes in this week's edition of Barron's. Hertz looks like the best of the bunch. It remains highly profitable, leads peers in adding electric vehicles to its fleet, and has bought back over 30% of its stock since it emerged from bankruptcy in mid-2021, the author notes. 4. Warner Bros.' (WBD) "Magic Mike's Last Dance" won Super Bowl weekend at the domestic box office with an estimated $8.2M from 1,550 locations. Overseas, the movie grossed an estimated $10.4M from 18 markets for a global cume of $18.6M. 5. PepsiCo (PEP) and Toast (TOST) saw positive mentions in this week's edition of Barron's.

16:30 EST Ocular Therapeutix announces interim 10-month data from Phase 1 OTX-TKI trial - Ocular Therapeutix announced interim 10-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the company's axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration, diabetic retinopathy and other retinal diseases. The ongoing U.S.-based Phase 1 clinical trial is a prospective, multi-center, randomized, controlled study in subjects previously treated with anti-VEGF therapy that is evaluating a 600 microgram dose of OTX-TKI in a single implant, with a 2 mg aflibercept injection four weeks after the implant, compared to 2 mg aflibercept injections administered every 8 weeks. The trial is designed to assess the safety, durability and tolerability of OTX-TKI, and to assess biological activity in subjects by measuring best corrected visual acuity and central subfield thicknessof the retina. The clinical trial enrolled a total of 21 subjects at six clinical sites in the U.S., who were randomized 3:1 to an arm receiving a single OTX-TKI implant, with a 2 mg aflibercept injection after implant, and an arm receiving aflibercept injections every 8 weeks. One subject in the OTX-TKI arm was not treated per protocol and has been removed from the efficacy analysis, as the subject incorrectly received aflibercept instead of a sham injection at Month 3 and 5 visits. As of the data cutoff of December 12, 2022, in the U.S.-based Phase 1 clinical trial, the single OTX-TKI implant continued to be generally well tolerated with no drug-related ocular or systemic serious adverse events observed through 10 months. As the company previously announced at the 7-month readout, one SAE of endophthalmitis was observed in the OTK-TKI arm which occurred following the mandated aflibercept injection at Month 1 and was assessed by the investigator as related to the injection procedure. There were no elevated IOP, retinal detachment, retinal vasculitis, or implant migration into the anterior chamber adverse events observed in the OTX-TKI arm, and no subjects had dropped out of either arm as of the data cutoff. The interim results showed subjects treated with a single OTX-TKI implant demonstrated stable and sustained and CSFT in the OTX-TKI arm at 10 months, which was comparable with the aflibercept arm. The 73% of subjects who were rescue-free up to Month 7, continued to demonstrate OTX-TKI's extended duration of action and remained rescue-free up to Month 10. Overall, a 92% reduction in treatment burden was observed in OTX-TKI treated subjects for up to 10 months.